Navigation Links
Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis

The first Phase III study involving the use of Actemra in the treatment of rheumatoid arthritis has revealed that it is superior to conventional treatment modality that uses disease modifying anti-rheumatic drugs (DMARDs to inhibit // joint destruction. It has also been found to provide symptomatic relief and improve sensation of pain.

Rheumatoid arthritis is a debilitating autoimmune disease in which the lining of the joints becomes inflamed causing irreversible joint damage and destruction. Actemra (tocilizumab) is a humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody. A monoclonal antibody is used to denote antibodies derived from genetically identical group of cells, a clone. The novel mechanism of action of the antibody can eventually pave way for a new therapeutic option for the treatment of RA. Nearly 306 patients with early aggressive rheumatoid patients were taken up for the study and were randomized to receive either Actemra as monotherapy or traditional treatment. Actemra was administered at 8 mg/kg I.V for every three weeks while the other group underwent treatment for 52 weeks. The administration of anti-TNF agents and leflunomide were restricted in the control group.

At the end of the study, the results were compared which revealed that there was a substantial reduction in the progression of joint damage over a 1-year period. Actemra was superior to DMARDs in preventing both erosion and joint space narrowing. Furthermore, the results are more promising in patients with early, aggressive disease.

The tolerability of the monotherapy was comparatively much higher in the Actemra group. Although there was a slight increase in the cholesterol level initially, it soon stabilized around the upper limit of normal. There was no incidence of tuberculosis in the group studied.

Similar clinical trials are being conducted in Europe and US to determine the efficacy and safety of Actemra in combinati on with other anti-rheumatoid medications. Head of Global Pharma Development, Roche, expressed his hope regarding the outcome of the clinical trials, expected to be released in the near future.
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... ... May 03, 2016 , ... University of ... today the launch of its Associates and Bachelor's degrees in Health Studies. Leading ... Rockefeller University, Dr. Torsten N. Wiesel; Chairman and CEO of Fortune 500® company ...
(Date:5/3/2016)... Houston, Texas (PRWEB) , ... May 03, 2016 ... ... company, today announced that it is launching a new client service center in ... in Houston, Texas, and will provide the full range of Empyrean client services. ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nationally recognized personal injury law firm Monge & ... giving free roses to anyone who wants one for their Mother or any other mother ... important valuable contributions of Mothers.” Monge goes on to say, “we are choosing to ...
(Date:5/3/2016)... Texas (PRWEB) , ... May 03, 2016 , ... Park ... that live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, ... Lawn/Uptown, Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... announces Benefits Alliance Insurance Services as the latest addition to its elite stable ... comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The Firm is ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- As a teenager, an active and athletic Randy ... heart. He continued enjoying sports and recreation throughout his ... was giving out and he was a few hours ... Mesa, Arizona resident received a ... transplant, the SynCardia TAH-t is the only approved device ...
(Date:5/3/2016)... , May 3, 2016  While you may be familiar with watching a film or TV ... known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller ... technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... 3, 2016 Pharmaceutical giant Johnson ... to a woman who says its talc-based powder products ... Gloria Ristesund $5 million in compensatory damages and ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This is ... company. In February, the same court awarded $72 million ...
Breaking Medicine Technology: